8-cyclopropyl-6-(2,6-dichlorophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one | 1431323-96-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 8-cyclopropyl-6-(2,6-dichlorophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one
• 英文别名: 8-Cyclopropyl-6-(2,6-dichlorophenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-5-one；8-cyclopropyl-6-(2,6-dichlorophenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-5-one
• CAS: 1431323-96-4
• 化学式: C₁₇H₁₃Cl₂N₃OS
• 分子量: 378.282
• InChiKey: GYMIYRVMOGETBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  71.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-cyclopropyl-6-(2,6-dichlorophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one 在 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 16.0h， 生成 8-cyclopropyl-6-(2,6-dichlorophenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrido[2,3-d]pyrimidin-5(8H)-one
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017
• 作为产物：
  描述：

  1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone 以 异丙醇 为溶剂， 反应 17.5h， 生成 8-cyclopropyl-6-(2,6-dichlorophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017

文献信息

• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130102590A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式（I）的化合物或药用可接受的盐，其中R1、R2、R3、R4和B在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• US9181239B2
  申请人：——

  公开号：US9181239B2

  公开（公告）日：2015-11-10
• [EN] PYRIDOPYRIMIDINONE INHIBITORS OF KINASES<br/>[FR] COMPOSÉS DE PYRIDOPYRIMIDINONE INHIBITEURS DE KINASES
  申请人：ABBVIE INC

  公开号：WO2013059485A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.